Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Summary of COVID-19 Antiviral Theraputics Flowchart - Alternative Text

The Summary of COVID-19 Antiviral Therapuetics flowchart illustrates the use of the antiviral treatments based on their potential to reduce progression to severe disease and hospitalization in high risk patients as of July 1, 2021:

Severity of Infection Patient Health Status Antiviral Treatment
No IllnessHealth, no infection 
Exposed/Asymptomatic InfectedNot hospitalized, no limitations 
Early Symptomatic

Hospitalized, with limitations

Moncolonal Antibodies (EUA Issued)

  • Bamlanivimab + Etesevimab1 (Lilly)
  • Casirivimab + Imdevimab (RGN)
  • Sotrovimab (GSK/Vir)
Hospital Admission
  • Hospitalized no acute medical problems
  • Hospitalized, not on oxygen
  • Hospitalized on oxygen
  • Remdesivir (FDA approved)
  • Tocilizumab (EUA issued)
ICU Admission
  • Hospitalized, high flow oxygen/non-invasive ventilation
  • Hospitalized, mechanical ventilation/ECMO

1.National shipment pause due to variants, as of 06/25/2021

COVID-19 Monoclonal Antibody Therapeutics

  • This page last reviewed: July 13, 2021